Under construction – not a live service
Sign in
Taking people in SpainNo phase

Controlled breathing exercises added to an exercise program in people with multiple myeloma

Tests adding breathing exercises to exercise and education in adults with multiple myeloma.

Plain-language title generated from the registry record
Registry title: Effects of Controlled Breathing on Cardiorespiratory Variables in Multiple Myeloma

Key facts

Where
Madrid, SpainSee the site

Where in Spain

  • Hospital Universitario 12 de OctubreMadrid, SpainTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Universidad Complutense de Madrid
Trial code
NCT07376733
Record updated
1 October 2026
Original description
A randomized, parallel, double-blind, controlled, clinical trial. Two groups of participants will be included, both receiving a therapeutic exercise intervention and an educational session on the importance of proper breathing over a 6-week period. One of the groups will additionally perform a home-based controlled breathing exercise protocol. Pre- and post-intervention assessments (6 weeks) will be conducted, along with a follow-up evaluation 4 weeks after completion of the intervention. The goal is to determine the effectiveness of adding a controlled breathing exercise program to a therapeutic exercise intervention on cardiorespiratory variables in individuals with multiple myeloma.Read full original descriptionShow less

Efficacy of a Controlled Breathing and Therapeutic Exercise Program on Cardiorespiratory Variables in Patients With Multiple Myeloma

A randomized, parallel, double-blind, controlled, clinical trial. Two groups of participants will be included, both receiving a therapeutic exercise intervention and an educational session on the importance of proper breathing over a 6-week period. One of the groups will additionally perform a home-based controlled breathing exercise protocol. Pre- and post-intervention assessments (6 weeks) will be conducted, along with a follow-up evaluation 4 weeks after completion of the intervention. The goal is to determine the effectiveness of adding a controlled breathing exercise program to a therapeutic exercise intervention on cardiorespiratory variables in individuals with multiple myeloma.

Inclusion: Age ≥ 18 years; Confirmed diagnosis of multiple myeloma, currently undergoing active treatment with daratumumab, and under clinical follow-up by the Hematology Department of HU12O; Explicit medical indication for supervised physical activity issued by the responsible hematologist and documented in the medical record; No scheduled hematopoietic stem cell transplantation within the 60 days following the planned start date of the intervention (verified through medical record review); Functional status of ECOG 0-2 (Eastern Cooperative Oncology Group), assessed by a healthcare professional from the Hematology Department, ensuring the ability to perform at least basic and light instrumental activities of daily living, including independent ambulation; Access to a smartphone with stable internet connection, required for monitoring and recording adherence to the intervention; Ability to provide written informed consent, demonstrating understanding of the study's nature, purpose, and procedures.

Exclusion: Medical risk contraindicating exercise or breathing techniques:; Clinically significant cardiovascular disease, including:decompensated heart failure, acute myocardial infarction within the past 3 months, clinically uncontrolled arrhythmias, unstable angina, acute-phase deep vein thrombosis or pulmonary embolism, pacemakers or cardiac devices whose monitoring parameters contraindicate supervised exercise according to cardiology; Severe decompensated respiratory disease, such as acute exacerbation of COPD, severe respiratory insufficiency, or persistently low resting oxygen saturation < 90% (not correctable); Functional or procedural limitations:; Inability to remain in the supine position for ≥ 5 minutes, required for part of the breathing intervention; Confirmed pregnancy or reasonable suspicion of pregnancy; Severe cognitive impairment, major psychiatric disorders, or neurological diseases that limit understanding of the procedures or safe participation; Significant difficulty understanding the language (spoken or written) that prevents following essential instructions or completing validated questionnaires; Hematologic or systemic conditions contraindicating exercise:; Severe anemia: hemoglobin < 9 g/dL in women or < 8 g/dL in men (latest laboratory test ≤ 14 days); Active systemic infection contraindicating exercise, fever ≥ 38 °C, or neutropenia < 0.5 × 10⁹/L; Severe cytopenias that, in the opinion of the hematologist, preclude moderate exercise; High musculoskeletal or bone risk:; Extensive lytic bone lesions, high risk of pathological fracture, or unstable vertebral fracture, documented by imaging or based on the assessment of the Hematology/Traumatology specialist; Uncontrolled pain that prevents safe participation in an exercise program.

ClinicalTrials.gov NCT07376733